Cargando…

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review

Gastric cancer is a common digestive tract tumor and the second most prevalent cancer. The prognosis of advanced gastric cancer is poor. Conversion therapy can reduce tumor burden, downgrade tumor, and increase the possibility of complete resection, thus prolonging the survival time of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Dingyi, Xu, Yunyun, Chen, Yunwang, Jiang, Jiahong, Wang, Mingxing, Yang, Min, Chen, Zheling, Yang, Liu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381218/ https://www.ncbi.nlm.nih.gov/pubmed/32765260 http://dx.doi.org/10.3389/fphar.2020.01027

Ejemplares similares

Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review
por: Wang, Mingxing, et al.
Publicado: (2020)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial
por: Xu, Zhiyuan, et al.
Publicado: (2021)

Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
por: Wang, Mingxing, et al.
Publicado: (2021)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
por: Lv, Huifang, et al.
Publicado: (2023)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
por: Zhang, Hong-Hong, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats
por: Dong, Shi-Qi, et al.
Publicado: (2022)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
por: Wang, Kunlun, et al.
Publicado: (2020)

Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial
por: Wang, Kang-Xin, et al.
Publicado: (2021)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial
por: Pan, Lanlan, et al.
Publicado: (2022)

Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients
por: Dai, Xichao, et al.
Publicado: (2016)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
por: Fu, Shengya, et al.
Publicado: (2022)

Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
por: Ye, Zaisheng, et al.
Publicado: (2021)

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
por: Ye, Zhize, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients
por: Huang, Da, et al.
Publicado: (2022)

WZB117 enhanced the anti-tumor effect of apatinib against melanoma via blocking STAT3/PKM2 axis
por: Zhang, Ren-Shu, et al.
Publicado: (2022)

Management and Thinking on the Treatment of Cancer Patients During the COVID-19
por: Pan, Shuangyue, et al.
Publicado: (2021)

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
por: Liu, Ying-ying, et al.
Publicado: (2019)

Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis
por: Peng, Dan, et al.
Publicado: (2023)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
por: Liu, Hongrui, et al.
Publicado: (2022)

The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study
por: Zhang, Chenghai, et al.
Publicado: (2022)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Pei, Fajun, et al.
Publicado: (2021)

Pathological complete remission of a locally advanced gastric cancer by neoadjuvant therapy “sandwich” regimen as SOXAP+ fluorescence laparoscopic surgery +SOXAP: Case report
por: Ma, Yanling, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report
por: Gao, Fangfang, et al.
Publicado: (2023)

Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward
por: Fornaro, Lorenzo, et al.
Publicado: (2016)

Concurrent apatinib and local radiation therapy for advanced gastric cancer: A case report and review of the literature
por: Zhang, Ming, et al.
Publicado: (2017)

SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer
por: Liu, Peng, et al.
Publicado: (2018)

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
por: Cai, Changjing, et al.
Publicado: (2022)

The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
por: Chen, Ke, et al.
Publicado: (2021)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review
por: Zheng, Zhipeng, et al.
Publicado: (2017)

Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2018)

A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
por: Zhang, Dan, et al.
Publicado: (2019)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer
por: Liu, Haipeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tr410uv962c5svttt2nh108l43